Gene · 1902
Papers2,112
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,112
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DYT-THAP1: exploring gene expression in fibroblasts for potential biomarker discovery. | Neurogenetics | 2024 | 38498291 | PubTator, text mining | PubMed |
| Peroxygenase-Catalyzed Allylic Oxidation Unlocks Telescoped Synthesis of (1S,3R)-3-Hydroxycyclohexanecarbonitrile. | ACS Catal | 2024 | 38449536 | PubTator, text mining | PubMed |
| Identification of inflammation-related biomarkers in keloids. | Front Immunol | 2024 | 38444850 | PubTator, text mining | PubMed |
| Global Proteomics Analysis of Lysophosphatidic Acid Signaling in PC-3 Human Prostate Cancer Cells: Role of CCN1. | Int J Mol Sci | 2024 | 38396744 | PubTator, text mining | PubMed |
| Alteration of chromosome structure impacts gene expressions implicated in pancreatic ductal adenocarcinoma cells. | BMC Genomics | 2024 | 38395755 | PubTator, text mining | PubMed |
| Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer's, and diabetes. | Sci Rep | 2024 | 38383841 | PubTator, text mining | PubMed |
| Lysophosphatidic acid (LPA) receptor-mediated signaling and cellular responses to anticancer drugs and radiation of cancer cells. | Adv Biol Regul | 2024 | 38377635 | PubTator, text mining | PubMed |
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold. | J Med Chem | 2024 | 38349223 | PubTator, text mining | PubMed |
| Identification and Validation of a Novel Anoikis-Related Gene Signature for Predicting Survival in Patients With Serous Ovarian Cancer. | World J Oncol | 2024 | 38274727 | PubTator, text mining | PubMed |
| Autotaxin and Lysophosphatidate Signaling: Prime Targets for Mitigating Therapy Resistance in Breast Cancer. | World J Oncol | 2024 | 38274724 | PubTator, text mining | PubMed |
| Special Issue IJMS-Molecular Mechanisms of Diabetic Kidney Disease. | Int J Mol Sci | 2024 | 38255864 | PubTator, text mining | PubMed |
| Involvement of Lysophospholipids in Pulmonary Vascular Functions and Diseases. | Biomedicines | 2024 | 38255229 | PubTator, text mining | PubMed |
| The implications for urological malignancies of non-coding RNAs in the the tumor microenvironment. | Comput Struct Biotechnol J | 2024 | 38249783 | PubTator, text mining | PubMed |
| The evolution of in vitro models of lung fibrosis: promising prospects for drug discovery. | Eur Respir Rev | 2024 | 38232990 | PubTator, text mining | PubMed |
| Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis. | Comput Struct Biotechnol J | 2024 | 38226313 | PubTator, text mining | PubMed |
| Dynamics of macrophage polarization support Salmonella persistence in a whole living organism. | Elife | 2024 | 38224094 | PubTator, text mining | PubMed |
| Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors. | PeerJ | 2024 | 38223763 | PubTator, text mining | PubMed |
| Identification of sulfur metabolism-related gene signature in osteoarthritis and TM9SF2's sustenance effect on M2 macrophages' phagocytic activity. | J Orthop Surg Res | 2024 | 38218914 | PubTator, text mining | PubMed |
| Single-cell genomics analysis reveals complex genetic interactions in an in vivo model of acquired BRAF inhibitor resistance. | NAR Cancer | 2024 | 38213996 | PubTator, text mining | PubMed |
| Regulatory mechanisms of circular RNAs during human mesenchymal stem cell osteogenic differentiation. | Theranostics | 2024 | 38164139 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1902/papers?page=7